1-10 of 10
Matthew Taylor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT209: A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348)

John Powderly, Manish Patel, Paul Woodard, Luke Chung, Hongyu Tian, Elizabeth Wieland, Kyu Hong, Maria Jose Costa, X. Charlene Liao, Matthew Taylor
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT209.
DOI: https://doi.org/10.1158/1538-7445.AM2022-CT209
Published: 15 June 2022
View article
Journal Articles

Abstract CT149: SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors

Nilo Azad, Drew Rasco, Sunil Sharma, Matthew Taylor, Christine Quaranto, David L. Tamang, Robert Nordness, Michael L. Meyers, Serap Sankoh, Peter Ordentlich, Anthony W. Tolcher
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT149.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT149
Published: 15 August 2020
View article
Journal Articles

Abstract CT242: SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors

Anthony W. Tolcher, Drew Rasco, Sunil Sharma, Matthew Taylor, Christine Quaranto, David L. Tamang, Robert Nordness, Michael L. Meyers, Serap Sankoh, Peter Ordentlich, Nilo Azad
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT242.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT242
Published: 15 August 2020
View article
Journal Articles

Abstract 973: The mitochondrial deoxyguanosine kinase regulates lung adenocarcinoma cancer stem-like cells through AMPK/YAP1 signaling

Shengchen Lin, Chongbiao Huang, Jianwai Sun, Xiuchao Wang, Jiaxin Kang, Matthew Taylor, Bin Fang, Pankaj K Singh, John Koomen, Jihui Hao, Shengyu Yang
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 973.
DOI: https://doi.org/10.1158/1538-7445.AM2019-973
Published: 01 July 2019
View article
Journal Articles

Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

David Hyman, Shivaani Kummar, Anna Farago, Birgit Geoerger, Morten Mau-Sorensen, Matthew Taylor, Elena Garralda, Ramamoorthy Nagasubramanian, Michael Natheson, Lucy Song, Michael Capra, Mette Jorgensen, Alan Ho, Neerav Shukla, Steve Smith, Xin Huang, Brian Tuch, Nora Ku, Theodore W. Laetsch, Alexander Drilon, David Hong
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT127.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT127
Published: 01 July 2019
View article
Journal Articles

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors

Vivek Subbiah, Matthew Taylor, Jessica Lin, Mimi Hu, Sai-Hong Ignatius Ou, Marcia S. Brose, Elena Garralda, Corinne Clifford, Michael Palmer, Erica Evans, Hongliang Shi, Beni Wolf, Justin F. Gainor
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT043.
DOI: https://doi.org/10.1158/1538-7445.AM2018-CT043
Published: 01 July 2018
View article
Journal Articles

Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

David S. Hong, Anna F. Farago, Marcia S. Brose, Howard A. Burris, Afshin Dowlati, Todd M. Bauer, Matthew Taylor, Alice T. Shaw, Adriana Estrada-Bernal, Anh T. Lee, Nisha Nanda, Michael C. Cox, Robert C. Doebele
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT008.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT008
Published: 15 July 2016
View article
Journal Articles

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

Michael Postow, Jason Chesney, Anna Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald Linette, Nicolas Meyer, Jeffrey Giguere, Sanjiv Agarwala, Montaser Shaheen, Marc Ernstoff, David Minor, April Salama, Matthew Taylor, Patrick Ott, Joel Jiang, Christine Horak, Paul Gagnier, Jedd Wolchok, F. Stephen Hodi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT002.
DOI: https://doi.org/10.1158/1538-7445.AM2016-CT002
Published: 15 July 2016
View article
Journal Articles

Hypoxia-Inducible Factor-2α Activation Promotes Colorectal Cancer Progression by Dysregulating Iron Homeostasis

Xiang Xue, Matthew Taylor, Erik Anderson, Cathy Hao, Aijuan Qu, Joel K. Greenson, Ellen M. Zimmermann, Frank J. Gonzalez, Yatrik M. Shah
Journal: Cancer Research
Cancer Res (2012) 72 (9): 2285–2293.
DOI: https://doi.org/10.1158/0008-5472.CAN-11-3836
Published: 30 April 2012
View article
PDF
Includes: Supplementary data
Journal Articles

BRMS1 transcription is repressed by DNA methylation and functions as both a metastasis and a tumor suppressor gene in non-small cell lung cancer

Yuan Liu, Philip Smith, Matthew Taylor, David Jones
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 326.
Published: 01 May 2008
View article